The Dallas Cowboys have been named a 'top landing spot' for Cooper Kupp if he leaves the Los Angeles Rams in the offseason.

Those closest to Eli Manning through the years don't believe his case for Pro Football Hall of Fame is complicated at all. This is their quarterback.

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five years from now. Berkshire Hathaway is hardly doomed. It's not even expected to lose value.

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and the blockbuster type 2 diabetes drug Mounjaro,

On Thursday, the Atlanta Braves signed outfielder Jurickson Profar to a three-year contract. It represents the first significant move for the Braves this offsea

There are many ways to diversify beyond the S&P 500. One is to hold shares of the Invesco S&P 500 Equal Weight ETF RSP. Another, according to Davis, is to take an even broader index-fund approach. One example is the Vanguard Total Stock Market ETF VTI, which is designed to track the entire U.S. market.

In the UK, the final round of the Cyclocross World Cup in Hoogerheide with Mathieu van der Poel will be broadcast on TV on Eurosport 2 and online on Discovery+. To get Eurosport's cycling coverage online, the 'standard' subscription to Discovery+ is all you need, which will set you back a modest £6.99 a month.

How the first Budget of Modi government 3.0 had unveiled big initiatives for massive employment generation and skilling of the teeming young population

Did you know that Gabriel Basso once played vice president JD Vance in a film about his younger years?

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target